The chemokine ligand CCL2 and its receptor CCR2 are implicated in the initiation and
progression of various cancers. CCL2 can activate tumour cell growth and proliferation …

Cancer is a leading cause of death worldwide, and cancer development is often associated
with disturbances in the autophagy process. Autophagy is a catabolic process involved in …

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor derived from bile duct
epithelium. Its characteristics include an insidious onset and frequent recurrence or …

Background Many anti-angiogenic agents have the potential to modulate the tumor
microenvironment and improve immunotherapy. Anlotinib has demonstrated anti-tumor …

Tumor microenvironment (TME) formation is a major cause of immunosuppression. The TME
consists of a considerable number of macrophages and stromal cells that have been …

Chimeric antigen receptor (CAR) T cell therapy faces a number of challenges for the
treatment of non-small-cell lung carcinoma (NSCLC), and efficient migration of circulating …

Purpose Tumor growth relies on the sufficient blood supply and continuously requires new
blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med …

Background Hypoxia-induced angiogenesis functions importantly in anaplastic thyroid
cancer (ATC) progression. However, the therapeutic potential of broad-spectrum anti …

Abstract Background Circulating tumour DNA (ctDNA)-based sequencing might provide a
simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to …

Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐
small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is …